EdgarLookup

Oruka Therapeutics, Inc. — All Filings

1,000 total filings on record

Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.

Overview All Filings Financials Insiders
All 10-K 10-K/A 10-K405 10-Q 10-Q/A 144 3 3/A 4 4/A 424B2 424B3 424B4 424B5 425 5 8-A12G 8-K 8-K/A ARS CORRESP CT ORDER D DEF 14A DEFA14A EFFECT POS AM PRE 14A PRER14A RW S-1 S-1/A S-1MEF S-3 S-3/A S-3ASR S-3MEF S-4 S-4/A S-8 S-8 POS SC 13D SC 13D/A SC 13G SC 13G/A SCHEDULE 13D/A SCHEDULE 13G SCHEDULE 13G/A SEC STAFF LETTER UPLOAD
Form Description Accession Number Filed Period
8-K CURRENT REPORT 0001213900-25-050756 Jun 3, 2025 Jun 2, 2025
4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-010822 Jun 3, 2025 Jun 2, 2025
4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-010826 Jun 3, 2025 Jun 2, 2025
4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-010825 Jun 3, 2025 Jun 2, 2025
SCHEDULE 13G 0000950170-25-072013 May 15, 2025
424B3 PROSPECTUS SUPPLEMENT 0001213900-25-043374 May 14, 2025
10-Q QUARTERLY REPORT 0001213900-25-043279 May 14, 2025 Mar 31, 2025
SCHEDULE 13G 0001172661-25-001776 May 13, 2025
ARS ANNUAL REPORT 0001213900-25-033326 Apr 18, 2025 Dec 31, 2024
DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-25-033322 Apr 18, 2025
DEF 14A PROXY STATEMENT 0001213900-25-033316 Apr 18, 2025 Jun 2, 2025
EFFECT 9999999995-25-000640 Mar 11, 2025
SCHEDULE 13D/A 0001213900-25-022364 Mar 10, 2025
10-K ANNUAL REPORT 0001213900-25-021165 Mar 6, 2025 Dec 31, 2024
S-8 REGISTRATION STATEMENT 0001213900-25-021200 Mar 6, 2025
POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 0001213900-25-021251 Mar 6, 2025
4 0001415889-25-005908 Feb 27, 2025 Feb 10, 2025
SCHEDULE 13G/A 0001415889-25-005913 Feb 27, 2025
3 0001415889-25-005906 Feb 27, 2025 Feb 10, 2025
8-K CURRENT REPORT 0001213900-25-010525 Feb 5, 2025 Feb 4, 2025
4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-001087 Jan 24, 2025 Jan 22, 2025
4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-001088 Jan 24, 2025 Jan 22, 2025
4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-001089 Jan 24, 2025 Jan 22, 2025
4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-001085 Jan 24, 2025 Jan 22, 2025
8-K CURRENT REPORT 0001213900-24-110303 Dec 19, 2024 Dec 17, 2024
EFFECT 9999999995-24-003588 Nov 26, 2024
UPLOAD 0000000000-24-012994 Nov 22, 2024
CORRESP 0001213900-24-101587 Nov 22, 2024
4 0001213900-24-101116 Nov 21, 2024 Nov 19, 2024
SC 13D/A AMENDMENT NO. 2 TO SCHEDULE 13D 0001213900-24-101117 Nov 21, 2024
8-K CURRENT REPORT 0001213900-24-099645 Nov 18, 2024 Nov 14, 2024
SC 13G/A JANUS CLOSEOUT 0001274173-24-000089 Nov 14, 2024
8-K CURRENT REPORT 0001213900-24-098530 Nov 14, 2024
S-8 REGISTRATION STATEMENT 0001213900-24-098574 Nov 14, 2024
S-1 REGISTRATION STATEMENT 0001213900-24-097737 Nov 14, 2024
SC 13G/A SC 13G/A 0001104659-24-119331 Nov 14, 2024
SC 13G/A 0001013594-24-000956 Nov 14, 2024
SC 13G/A 0000919574-24-006793 Nov 14, 2024
10-Q QUARTERLY REPORT 0001213900-24-097443 Nov 13, 2024 Sep 30, 2024
SC 13D/A 0000902664-24-005943 Oct 22, 2024
DEF 14A DEF 14A 0001140361-24-043698 Oct 18, 2024 Nov 14, 2024
PRE 14A PRE 14A 0001140361-24-042965 Oct 7, 2024 Nov 14, 2024
SC 13G 0000315066-24-002024 Oct 7, 2024
8-K CURRENT REPORT 0001213900-24-085543 Oct 4, 2024 Oct 3, 2024
8-K CURRENT REPORT 0001213900-24-078549 Sep 13, 2024 Sep 11, 2024
4 0001213900-24-078633 Sep 13, 2024 Sep 11, 2024
SC 13D/A AMENDMENT NO. 1 TO SCHEDULE 13D 0001213900-24-078635 Sep 13, 2024
3 0001213900-24-076588 Sep 6, 2024 Aug 29, 2024
3 0001213900-24-076589 Sep 6, 2024 Aug 29, 2024
3 0001213900-24-076591 Sep 6, 2024 Aug 29, 2024